重症肌无力的诊断策略与临床治疗研究进展

doi:10.3760/cma.j.cn441417-20250424-17007

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (17): 2851-2855.DOI: 10.3760/cma.j.cn441417-20250424-17007

重症肌无力的诊断策略与临床治疗研究进展

高一凡张威张子良陈金波

滨州医学院附属医院神经内科，滨州 256603

收稿日期:2025-04-24 出版日期:2025-09-01 发布日期:2025-09-25
通讯作者: 陈金波，Email：chenjinbo6720@126.com
基金资助:
山东省医药卫生科技发展计划（2019WS322）；国家自然科学基金（81701192）

Research progress on diagnostic strategies and clinical treatment of myasthenia gravis

Gao Yifan, Zhang Wei, Zhang Ziliang, Chen Jinbo

Department of Neurology, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2025-04-24 Online:2025-09-01 Published:2025-09-25
Contact: Chen Jinbo, Email: chenjinbo6720@126.com
Supported by:
Shandong Province Medical and Health Science and Technology Development Program (2019WS322); National Natural Science Foundation of China (81701192)

摘要/Abstract

摘要：

重症肌无力（MG）作为一种罕见的神经肌肉接头疾病，其诊断与治疗的进展对于患者预后及生活质量的提升具有深远影响。本文将系统阐述MG的诊断策略（临床诊断、血清抗体检测、电生理检查及药物学检测），并归纳其治疗方案（药物治疗、手术治疗及免疫治疗）。通过分析当前诊疗现状、最新研究进展及未来研究方向，为临床实践提供有价值的参考。

关键词:

重症肌无力, 诊断, 治疗, 进展

Abstract:

Myasthenia gravis (MG), as a rare neuromuscular junction disorder, the advancements in its diagnosis and treatment have a profound impact on the prognosis and quality of life of patients. This article will systematically elaborate on the diagnostic strategies of MG (clinical diagnosis, serum antibody testing, electrophysiological examination, and pharmacological testing), and summarize its treatment plans (pharmacological treatment, surgical treatment, and immunotherapy). By analyzing the current medical treatment situation, the latest research progress and the future research directions, valuable references are provided for clinical practice.

Key words:

Myasthenia gravis, Diagnosis, Treatment, Progress

高一凡张威张子良陈金波.

重症肌无力的诊断策略与临床治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(17): 2851-2855.

Gao Yifan, Zhang Wei, Zhang Ziliang, Chen Jinbo.

Research progress on diagnostic strategies and clinical treatment of myasthenia gravis [J]. International Medicine and Health Guidance News, 2025, 31(17): 2851-2855.

参考文献

[1] Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis[J]. Nat Rev Dis Primers, 2019, 5(1):30. DOI: 10.1038/s41572-019-0079-y.
[2] 张华,闻洁曦. 重症肌无力诊治进展[J]. 中国神经免疫学和神经病学杂志,2020,27(1):6-8.DOI:10.3969/j.issn.1006-2963.2020.01.002.
[3] 王秀云,许贤豪,孙宏,等. 重症肌无力病人的临床绝对评分法和相对评分法[J]. 中华神经科杂志,1997,30(2):87-90.
[4] Barohn RJ, Mcintire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score[J]. Ann N Y Acad Sci, 1998, 841:769-772. DOI: 10.1111/j.1749-6632.1998.tb11015.x.
[5] De Moura CM, Magno GM. Ice pack test in myasthenic ptosis as an important tool for clinical practice[J]. J Clin Neuromuscul Dis, 2021, 23(2):110-111. DOI: 10.1097/CND.0000000000000338.
[6] 常婷,李柱一. 中国重症肌无力研究进展近十年回顾与展望[J]. 中国神经免疫学和神经病学杂志,2022,29(5):349-355. DOI:10.3969/j.issn.1006-2963.2022.05.001.
[7] 邹玲莉,蔡定军,陈学波. 间接免疫荧光法检测AchR抗体、MuSK抗体和LRP4抗体在重症肌无力诊断中的价值[J]. 中国实验诊断学,2021,25(5):654-657. DOI:10.3969/j.issn.1007-4287.2021.05.006.
[8] Gastaldi M, Scaranzin S, Businaro P, et al. Improving laboratory diagnostics in myasthenia gravis[J]. Expert Rev Mol Diagn, 2021, 21(6):579-590. DOI: 10.1080/14737159.2021.1927715.
[9] Li Z, Zhang C, Chang T, et al. A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study[J]. Lancet Reg Health West Pac, 2023, 38:100846. DOI: 10.1016/j.lanwpc.2023.100846.
[10] Katzberg HD, Abraham A. Electrodiagnostic assessment of neuromuscular junction disorders[J]. Neurol Clin, 2021, 39(4):1051-1070. DOI: 10.1016/j.ncl.2021.06.013.
[11] 中国免疫学会神经免疫分会. 中国重症肌无力诊断和治疗指南(2020版)[J]. 中国神经免疫学和神经病学杂志,2021,28(1):1-12. DOI:10.3969/j.issn.1006-2963.2021.01.001.
[12] Juel VC. Single fiber electromyography[J]. Handb Clin Neurol, 2019, 160:303-310. DOI: 10.1016/B978-0-444-64032-1.00019-9.
[13] Yang XG, Guo HY, Peng Z, et al. Application of electrophysiological techniques in assessing of neuromuscular junction-related disorders[J]. World Neurosurg, 2024, 191:165-171. DOI: 10.1016/j.wneu.2024.08.076.
[14] 武卫周,员丽娜,路美,等. MuSK抗体阳性的重症肌无力诊断及治疗最新进展[J]. 武警医学,2020,31(12):1080-1083.DOI: 10.14010/j.cnki.wjyx.2020.12.019.
[15] Crisafulli S, Boccanegra B, Carollo M, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future[J]. CNS Drugs, 2024, 38(1):15-32. DOI: 10.1007/s40263-023-01059-8.
[16] Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics[J]. Nat Rev Neurol, 2019, 15(2):113-124. DOI: 10.1038/s41582-018-0110-z.
[17] García ED, Pardo FJ. Myasthenia gravis. Update on diagnosis and therapy[J]. Med Clin (Barc), 2023, 161(3):119-127. DOI: 10.1016/j.medcli.2023.04.006.
[18] Zhen L, Zhao X, Li W, et al. Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study[J]. Front Neurol, 2023, 14:1259484. DOI: 10.3389/fneur.2023.1259484.
[19] Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis[J]. Autoimmun Rev, 2021, 20(1):102712. DOI: 10.1016/j.autrev.2020.102712.
[20] Bar J, Stahl B, Hod M, et al. Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience[J]. Am J Med Genet A, 2003, 116A(1):31-36. DOI: 10.1002/ajmg.a.10817.
[21] Verschuuren J. New therapies for autoimmune myasthenia gravis[J]. Lancet Neurol, 2023, 22(5):368-369. DOI: 10.1016/S1474-4422(23)00125-4.
[22] Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2021, 20(7):526-536. DOI: 10.1016/S1474-4422(21)00159-9.
[23] Howard JF, Vissing J, Gilhus NE, et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis[J]. Expert Opin Investig Drugs, 2021, 30(5):483-493. DOI: 10.1080/13543784.2021.1897567.
[24] Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Neurol, 2023, 22(5):395-406. DOI: 10.1016/S1474-4422(23)00080-7.
[25] 谭群友,陶绍霖,刘宝东,等. 重症肌无力外科治疗中国临床专家共识[J]. 中国胸心血管外科临床杂志,2022,29(5):529-541.DOI: 10.7507/1007-4848.202202043.
[26] Fernández-Fournier M, Kerguelen A, Rodríguez de Rivera FJ, et al. Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience[J]. Expert Rev Neurother, 2022, 22(10):897-903. DOI: 10.1080/14737175.2022.2147827.
[27] Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics[J]. Front Immunol, 2020, 11:212. DOI: 10.3389/fimmu.2020.00212.
[28] Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy[J]. Neurotherapeutics, 2021, 18(4):2397-2418. DOI: 10.1007/s13311-021-01108-4.
[29] 中国罕见病联盟神经罕见病专业委员会,中国罕见病联盟重症肌无力协作组,中华医学会神经病学分会神经肌肉病学组,等. 中国难治性全身型重症肌无力诊断和治疗专家共识(2024版)[J]. 中华神经科杂志,2024,57(8):840-847.DOI:10.3760/cma.j.cn113694-20240222-00106.
[30] Haghikia A, Hegelmaier T, Wolleschak D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis[J]. Lancet Neurol, 2023, 22(12):1104-1105. DOI: 10.1016/S1474-4422(23)00375-7.

重症肌无力的诊断策略与临床治疗研究进展

Research progress on diagnostic strategies and clinical treatment of myasthenia gravis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵洲刘为朋李宗睿王睿智胡宝光. 高血压大鼠模型的研究现状 [J]. 国际医药卫生导报, 2025, 31(9): 1465-1470.
[2]	昝兴淳. 通督调神针刺治疗脑卒中后吞咽障碍的研究进展与展望 [J]. 国际医药卫生导报, 2025, 31(9): 1470-1474.
[3]	郝鑫郭威谭丹丹郭金燕马宁兰玉怀. 美罗培南联合连续性肾脏替代治疗脓毒症急性肾损伤的效果及对肾功能恢复的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1511-1515.
[4]	潘祁喻莉张安生. 铸瓷嵌体冠在短基牙后牙修复患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1554-1558.
[5]	陈娟娟. 中线导管在住院病区患者静脉治疗中的应用现状 [J]. 国际医药卫生导报, 2025, 31(9): 1565-1568.
[6]	何苑洵张凌烟黄君. 原发性乳腺血管肉瘤合并卵巢血管肉瘤的超声诊断1例并文献复习 [J]. 国际医药卫生导报, 2025, 31(8): 1250-1253.
[7]	李强. 超声引导下射频消融治疗甲状腺微小乳头状癌的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1258-1260.
[8]	洪金全黄震宇黄惠炆黄豪博. 胸苷酸合成酶基因在肿瘤发生发展中的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1260-1265.
[9]	蒋萌赵静如刘惠刘庆新. 自噬与缺血性脑血管疾病的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1265-1269.
[10]	刘汉清孙银萍赵强任帅. MSI-H/dMMR亚组局部晚期结直肠癌患者新辅助免疫治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1270-1274.
[11]	刘雪妮惠容容　邓庆. 多普勒超声与炎症指标诊断T2DM患者下肢血管病变的价值 [J]. 国际医药卫生导报, 2025, 31(8): 1337-1342.
[12]	卫晓娟李新锋郭团茂. 骨髓细胞形态学联合Hb/RDW比值评估DLBCL CAR-T治疗失败的价值 [J]. 国际医药卫生导报, 2025, 31(8): 1364-1368.
[13]	张秋萍刘新琼任骞杨淼. 失效模式与效应分析的康复护理在冠心病合并糖尿病患者PCI围手术期中的效果 [J]. 国际医药卫生导报, 2025, 31(8): 1404-1408.
[14]	朱鹏唐文玲覃刚. 结直肠癌中微小RNA功能及临床价值进展 [J]. 国际医药卫生导报, 2025, 31(6): 886-890.
[15]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.